# Duchenne muscular dystrophy

Type: Technology

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/duchenne-muscular-dystrophy
Canonical HTML page: https://getlegalbrief.com/entity/duchenne-muscular-dystrophy

## Timeline

- **2026-03-11**: Document Request — Expected date for formal requests for internal FDA communications regarding DMD drug applications.
- **2026-03-10**: Investigation Announced — Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process.
- **2026-03-10**: Commissioner Consultation — Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy.

## Recent coverage (1 stories)

### Senator Johnson Launches Investigation into FDA Rare Disease Drug Denials
2026-03-10 22:17:42 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.
Full story: https://getlegalbrief.com/story/senator-johnson-fda-rare-disease-investigation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.